SAN DIEGO, Nov. 2, 2010 /PRNewswire/ -- Pfenex Inc. today announced the launch of a new business division, Reagent Proteins. Reagent Proteins will enhance the development scientists' ability to source complex reagent grade proteins at a competitive price.
Reagent Proteins will initially offer a product list in excess of 2300 proteins, including stem cell growth factors, cytokines, chemokines, and enzymes. A unique aspect of Reagent Proteins' offering includes vaccine carriers, adjuvants and antigens, available in both pre-clinical and cGMP quality grades. Reagent Proteins is the only protein supplier supporting human vaccine developers from discovery to commercialization with a broad range of vaccine components.
"As we continue to leverage our business based on efficient complex protein production, the Reagent Proteins business unit is an obvious choice," stated Bertrand C. Liang, Chief Executive Officer, "We have and continue to build a portfolio of proteins in areas of need, including those based upon monitoring of industry trends as well as direct feedback from the researchers themselves."
About Reagent Proteins
Reagent Proteins is a leading supplier of reagent, pre-clinical and cGMP grade proteins to the biopharmaceutical and vaccine development community. We ensure that scientists have ready access to a comprehensive offering of high quality proteins to enable their development efforts to proceed efficiently. www.reagentproteins.com
About Pfenex Inc.
Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com
SOURCE Pfenex Inc.